Anti-angiogenic therapies in cancer: from endogenous inhibitors to bispecific VEGF x PD-(L)1 antibodies.

Front Immunol · 2026 · PMC12876227 · PMID 41659853

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

The first global Phase 3 trial to evaluate ivonescimab plus chemotherapy (HARMONi) ( NCT06396065 ) in a post-EGFR TKI NSCLC setting showed an increase in PFS consistent with the HARMONi-A study and a positive trend in OS.

also in 6,846 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.